NVX-CoV2515
- Generic Name
- NVX-CoV2515
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
Phase 3
Completed
- Conditions
- COVID-19SARS CoV 2 Infection
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Novavax
- Target Recruit Count
- 1340
- Registration Number
- NCT05372588
- Locations
- 🇦🇺
Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
🇦🇺Paratus Clinical Research Brisbane, Albion, Queensland, Australia
🇦🇺Emeritus Research, Camberwell, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath